Promising Penny Stocks To Watch In May 2025

The United States market has shown positive momentum, with a 1.6% increase over the last week and a 12% rise over the past year, supported by an anticipated annual earnings growth of 14%. While penny stocks may seem like a term from another era, they continue to offer intriguing opportunities for investors seeking growth in smaller or newer companies at attractive price points. When these stocks are supported by strong financial health and solid fundamentals, they can present compelling investment options with potential upside that defies traditional risks often associated with this segment.

Top 10 Penny Stocks In The United States

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Organogenesis Holdings (NasdaqCM:ORGO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care, surgical, and sports medicine markets in the United States with a market cap of $390.71 million.

Operations: The company's revenue is derived entirely from its regenerative medicine segment, totaling $458.76 million.

Market Cap: $390.71M

Organogenesis Holdings Inc. is navigating the penny stock landscape with a market cap of US$390.71 million and revenue derived entirely from its regenerative medicine segment, totaling US$458.76 million in 2024. Despite being unprofitable, the company has no debt and its short-term assets exceed both short- and long-term liabilities, indicating financial stability amidst volatility. Recent earnings showed a net loss increase to US$18.84 million for Q1 2025 compared to the previous year, yet analysts anticipate significant price appreciation potential of 93.5%. The company's guidance suggests stable or slightly increasing revenues for 2025 with improved gross margins.

• Take a closer look at Organogenesis Holdings' potential here in our financial health report.
• Gain insights into Organogenesis Holdings' outlook and expected performance with our report on the company's earnings estimates.

Autolus Therapeutics (NasdaqGS:AUTL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing T cell therapies for cancer and autoimmune diseases, with a market cap of $353.95 million.

Operations: The company generates revenue of $9.01 million from its segment focused on developing and commercializing CAR-T therapies.

Market Cap: $353.95M

Autolus Therapeutics, with a market cap of US$353.95 million, is advancing in the penny stock arena through its focus on CAR-T therapies, generating US$9.01 million in revenue. Despite being unprofitable and facing increased net losses of US$70.16 million for Q1 2025, its short-term assets significantly exceed liabilities, and it maintains more cash than debt. The company recently secured conditional marketing authorization for AUCATZYL® from UK regulators and closed a shelf registration raising approximately US$69.32 million, indicating proactive financial management amid high volatility and ongoing clinical developments in cancer treatments.

• Dive into the specifics of Autolus Therapeutics here with our thorough balance sheet health report.
• Assess Autolus Therapeutics' future earnings estimates with our detailed growth reports.

Yatsen Holding (NYSE:YSG)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Yatsen Holding Limited, with a market cap of $479.54 million, develops and sells beauty products in China under brands such as Perfect Diary, Little Ondine, Pink Bear, Abby’s Choice, Galénic, DR.WU, Eve Lom, and EANTiM.

Operations: The company generates its revenue primarily from the People's Republic of China, amounting to CN¥3.45 billion.

Market Cap: $479.54M

Yatsen Holding Limited, with a market cap of $479.54 million, operates in the beauty sector primarily in China. Despite being unprofitable, it has shown progress by significantly reducing its net loss from CN¥124.6 million to CN¥5.3 million year-over-year for Q1 2025. The company's short-term assets surpass both long-term and short-term liabilities, and it remains debt-free with a stable cash runway exceeding three years. Recent initiatives include a share repurchase program up to $30 million funded by existing cash reserves, reflecting confidence in its financial position despite ongoing high volatility and negative return on equity at -18.97%.

• Get an in-depth perspective on Yatsen Holding's performance by reading our balance sheet health report here.
• Examine Yatsen Holding's earnings growth report to understand how analysts expect it to perform.

Where To Now?

• Click through to start exploring the rest of the 717 US Penny Stocks now.
• Curious About Other Options? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com